

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Acute myelogenous leukemia (AML)	AML1-ETO oncogenic fusion protein	<i>In vitro</i> and mouse studies suggest that preventing formation of AML1-ETO multimeric complexes could help treat AML. In two human cancer cell lines, AML1-ETO that was mutated at five residues necessary for multimer formation had less severe oncogenic properties than nonmutated AML1-ETO. Mice transplanted with bone marrow cells that expressed nonmutated AML1-ETO developed leukemia, whereas mice receiving transplants that expressed the mutant form of AML1-ETO did not. Ongoing work includes identifying compounds that inhibit the formation of AML1-ETO tetramers.	Patent and licensing status undisclosed	Wichmann, C. <i>et al. Blood</i> ; published online April 29, 2010; doi:10.1182/blood-2009-10-248047 <b>Contact:</b> Manuel Grez, Institute for Biomedical Research, Frankfurt, Germany e-mail: <a href="mailto:grez@em.uni-frankfurt.de">grez@em.uni-frankfurt.de</a>
		<b>SciBX 3(19); doi:10.1038/scibx.2010.581</b> Published online May 13, 2010		